Market Research Logo

Global Gastric Cancer Drugs Market 2016-2020

Market outlook of the global gastric cancer drugs market

Technavio’s market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market’s healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.

The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.

Geographical segmentation and analysis of the gastric cancer drugs market

  • Americas
  • APAC
  • Europe
In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.

Competitive landscape and key vendors

The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.

The top vendors in the market are -
  • Hoffmann-La Roche
  • Eli-lilly
  • Sanofi
  • Otsuka Holdings
Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.

Key questions answered in the report include
  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global gastric cancer drugs market?
  • What are the key market trends impacting the growth of the gastric cancer drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the vendors in the global gastric cancer drugs market?
  • Trending factors influencing the market shares of the Americas, APAC, and Europe?
  • What are the key outcomes of the five forces analysis of the gastric cancer drugs market?
Technavio also offers customization on reports based on specific client requirement.

Related report:
  • Global Colorectal Cancer Drugs Market 2015-2019
  • Global Colorectal Cancer Drugs Market 2015-2019
  • Global Cancer Pain Therapeutics Market 2015-2019


Press Release

Technavio Announces the Publication of its Research Report – Global Gastric Cancer Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Gastric Cancer Drugs Market: Hoffmann-La Roche, Eli-lilly, Sanofi and Otsuka Holdings
Other Prominent Vendors in the market are: Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Commenting on the report, an analyst from Technavio’s team said: “The dominance of the market by the usage of off-label drugs to treat gastric cancer patients is one of the trends, and is expected to be a preferred treatment option for the medical fraternity, patients, and the families of patients. This will in turn raise the number of treatment-seeking patients, which will result in an overall increase in consumption of medicines.”
According to the report, the presence of growing unmet needs for appropriate drugs are one of the major factors propelling the growth of the market.
Further, the report states that the shortage of drugs decreases the revenue generated by individual drugs. In addition, a shortage of drugs may lead to delays of chemotherapeutic treatments, thereby promoting the use of expensive and alternative treatments that are less efficacious and safe.

Companies Mentioned

Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
  • Disease overview
    • Understanding the disease
      • Table Types of gastric cancer
      • Table Frequency of different types of gastric cancers
    • Pathophysiology
    • Causes
      • Table Causes of gastric cancer
    • Signs and symptoms
      • Table Signs and symptoms of gastric cancer
    • Diagnosis
      • Table Diagnostic tests for gastric cancer
    • Staging
      • Table Staging of gastric cancer
    • Japanese staging system
    • Treatment
      • Table Treatment options for gastric cancer
      • Table First-line therapy for metastatic or locally advanced gastric cancer
      • Table Second-line therapy for gastric cancer
      • Table Surgeries for gastric cancer
      • Table Types of radiation therapy for gastric cancer
    • Epidemiology
      • Table Estimated number of new cancers (all ages) males and females in Americas, EMEA, and APAC: 2015 and 2020
      • Table Estimated number of new cancers (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
      • Table Estimated number of mortality cases (all ages) males and females in Americas, EMEA, and APAC: 2015
      • Table Estimated number of mortality cases (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
    • Economic burden
  • Pipeline portfolio
    • Table Pipeline molecules for gastric cancer
    • Table Gastric cancer clinical trials by development phase
    • Table Gastric cancer clinical trials by trial status
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global gastric cancer drugs market 2015-2020 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by molecule type
    • Table Global gastric cancer drugs market segmented by molecule type
    • Small molecules
    • Biologics
  • Market segmentation by route of administration
    • Table Global gastric cancer drugs market segmented by route of administration
    • Oral
      • Table Dose and administration schedule of Teysuno (S-1) plus cisplatin
    • Parenteral
  • Market segmentation by lines of chemotherapy
    • First-line chemotherapy
    • Second-line chemotherapy
      • Table Lines of therapy for the treatment of advanced gastric cancer
      • Table Estimated annual cost per patient for chemotherapy regimen in EU ($ millions)
  • Geographical segmentation
    • Global gastric cancer drugs market by geographical segmentation 2015-2020
      • Table Global gastric cancer drugs market by geographical segmentation 2015
      • Table Global gastric cancer drugs market region wise 2015-2020 ($ millions)
    • Gastric cancer drugs market in APAC
      • Table Gastric cancer drugs market in APAC 2015-2020 ($ millions)
    • Gastric cancer drugs market in Japan
      • Table Gastric cancer drugs market in Japan 2015-2020 ($ millions)
    • Gastric cancer drugs market in China
      • Table Gastric cancer drugs market in China 2015-2020 ($ millions)
      • Table Gastric cancer drugs market in Japan and China 2015-2020 ($ millions)
    • Gastric cancer drugs market in Americas
      • Table Gastric cancer drugs market in Americas 2015-2020 ($ millions)
    • Gastric cancer drugs market in EMEA
      • Table Gastric cancer drugs market in EMEA 2015-2020 ($ millions)
  • Market drivers
    • Table Key drivers for global gastric cancer drugs market
    • Promising drug pipeline
    • Unmet medical needs
    • Increase in patient population
    • Patient assistance programs
      • Table Number of patients treated with Herceptin via Patient Assistance Program in China
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Challenges of global gastric cancer drugs market
    • High cost of drugs
      • Table Average cost comparison of Herceptin
    • Adverse side effects
    • Shortage of drugs
    • Delayed diagnosis
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Trends of global gastric cancer drugs market
    • Rise in public awareness
    • Use of off-label drugs
    • Intense competition among vendors
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Eli Lilly
        • Table Timeline of Cyramza in US, EU, and Japan
        • Table Eli Lilly: Key takeaways
        • Table Timeline of Herceptin in US, EU, and Japan
        • Table F. Hoffmann-La Roche: Global YoY growth and revenue of Herceptin 2011-2014 ($ millions)
        • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in 67US 2013-2014 ($ millions)
        • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ millions)
        • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
        • Table F. Hoffmann-La Roche: Key takeaways
        • Table Timeline of Tegafur in Japan, EU, and Asia
        • Table Otsuka Holdings: Key takeaways
        • Table Timeline of Taxotere in 71US, EU, and Japan
        • Table Sanofi: Global YoY growth and revenue of Taxotere 2011-2014 ($ millions)
        • Table Sanofi: YoY growth and revenue of Taxotere in 72US 2011-2014 ($ millions)
        • Table Sanofi: YoY growth and revenue of Taxotere in EU 2011-2014 ($ millions)
        • Table Sanofi: Key takeaways
  • Key vendor analysis
    • Eli Lilly
      • Table Eli Lilly: Business segmentation by revenue 2014
      • Table Eli Lily: Business/Product segmentation by revenue 2012 and 2013 ($ millions)
      • Table Eli Lily: Geographical segmentation by revenue 2014
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Business segmentation by revenue 2014
      • Table F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
    • Otsuka Holdings
      • Table Otsuka Holdings: Business segmentation 2014 by revenue
      • Table Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Otsuka Holdings: Geographical segmentation by revenue 2014
    • Sanofi
      • Table Sanofi: Business segmentation by revenue 2014
      • Table Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Sanofi: Geographical segmentation by revenue 2014
    • Other prominent vendors
  • Appendix
    • List of abbreviation
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report